论文部分内容阅读
目的:通过对门静脉高压脾功能亢进大鼠药物诱导肝癌过程中进行脾脏切除,探讨门静脉高压脾功能亢进对大鼠肝癌发生率的影响。方法:将雌雄SD大鼠性别内分别分为对照组、脾亢组、脾亢切脾组,脾功能亢进大鼠模型采用门静脉缩窄术联合脾静脉结扎术进行制备,各组均予以DEN(二乙基亚硝胺)腹腔注射,按体重20mg/kg给药,每周3次,12周停药,14周处死。其中,脾亢脾切除组于给药第四周进行脾切除术,手术恢复期间持续给药。观察各组实验动物的肝脏大体变化及病理改变,计算成瘤率。结果:实际成瘤率显示脾亢组较对照组明显升高,而雄性脾亢切脾组的成瘤率较脾亢组有所降低。雌性脾亢切脾组成瘤率同脾亢组差异不明显。结论:门静脉高压脾功能亢进状态下进行脾切除,对于雄性能减低肝癌发生的风险,对于雌性的意义不大,给临床实际工作提供了新的思路。
OBJECTIVE: To study the effect of portal hypertension on the incidence of hepatocellular carcinoma (HCC) in rats by inducing splenectomy during drug-induced liver cancer in portal hypertensive rats with hypersplenism. Methods: The male and female SD rats were divided into control group, hypersplenism group, spleen hypersplenism group, hypersplenism rat model by portal vein narrowing combined with splenic vein ligation, the groups were given DEN ( Diethylnitrosamine) intraperitoneal injection, according to the body weight of 20mg / kg administration, three times a week, 12 weeks withdrawal, 14 weeks after sacrifice. Among them, the spleen hypersplenism group was given splenectomy in the fourth week of administration, and continued to be administered during the recovery period. Observe the general changes of the liver and pathological changes of experimental animals in each group to calculate the tumor formation rate. Results: The actual tumorigenic rate showed that the spleen hyperthyroidism group was significantly higher than the control group, while the male spleen hyperthyroidism spleen group tumorigenicity rate lower than hypersensitivity group. Female spleen hypersplenism spleen composition rate was not significantly different with hypersplenism. Conclusions: Splenectomy under portal hypertensive hypersplenism is of little significance to females because males can reduce the risk of liver cancer, which provides a new idea for clinical practice.